Arabian Gulf University Kingdom of Bahrain Year 5 Internal Medicine Critical Appraisal of Medical Article (2) Critical Appraisal (Form A)

Similar documents
Arabian Gulf University Kingdom of Bahrain Year 5 Internal Medicine Critical Appraisal of Medical Article (1) Critical Appraisal (Form A)

The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page

Journal Club September 29, Vanessa AKIKI PGYlII Internal Medicine

GLYCEMIC CONTROL SURVEY

DKA : Diabetic Ketoacidosis & HHS: Hyperlgycemic Hyperosmolar Syndrome Protocol. Glycemic Task Force September 2014

4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): High fat/low CHO March 2013

Basal Bolus Insulin Therapy Frequently Asked Questions

Subject Index. Breastfeeding, self-monitoring of blood glucose 56

AACN PCCN Review. Endocrine

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

With Dr. Sarah Reid and Dr. Sarah Curtis

Diabetic Ketoacidosis

DATE: 12 January 2017 CONTEXT AND POLICY ISSUES

Intensive Insulin in the Intensive Care Unit

ADMIT DIABETIC KETOACIDOSIS (DKA) PLAN - Phase: Begin Immediately/Emergency Center

Impact of a critical pathway on inpatient management of diabetic ketoacidosis Ilag L L, Kronick S, Ernst R D, Grondin L, Alaniz C, Liu L, Herman W H

CRITICAL APPRAISAL WORKSHEET 1

Urgent Medical Device Correction

For patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH

Robert M. Bernstein, MD, FACE Regional Endocrinology Associates, PC 1533 Saint Francis Drive Santa Fe, NM Cell: (505)

DIABETES MELLITUS. IAP UG Teaching slides

Index. Note: Page numbers of article titles are in boldface type.

DIABETIC KETOACIDOSIS (DKA) K E M I A D E Y E R I, P G Y - 1

Evidence for Basal Bolus Insulin Versus Slide Scale Insulin

Special Situations 1

DKA Adult ICU Powerplan

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

A Children s Bedtime Story

Type I Type II Insulin Resistance

Management of Hyperglycemic Crises

SARASOTA MEMORIAL HOSPITAL

Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis

LETTER TO THE EDITOR

Improving Glycemic Control in the Critical Care

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Insulin Prior Authorization with optional Quantity Limit Program Summary

The SIMPLE Model. Scientifically Informed Medical Practice and Learning

Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus

Intravenous Infusions

10.2 Strategies to Optimize Parenteral Nutrition and Minimize Risks: Use of lipids May 2015

SARASOTA MEMORIAL HOSPITAL NURSING PROCEDURE

P R O J E C T B U L L E T I N - F A L L I N T H I S I S S U E U P D A T E S F O R

Provincial Clinical Knowledge Topic Insulin Pump Therapy, Pediatric and Adult Acute Care V 1.0

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

Mark W.J. Strachan Brian M. Frier. Insulin Therapy. A Pocket Guide

Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children

Pathogenesis of disease diabetic ketoacidosis

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED HEALTH CARE

Diabetic Emergencies: Ketoacidosis and the Hyperglycemic Hyperosmolar State. Adam Bursua, Pharm.D., BCPS

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Special Situations. Askiel Bruno, MD, MS Protocol PI

Original Contributions

Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines

Developing a pathway of. and care planning for people with diabetes

Hypoglycemia Reduction STARTER PACK WEBINAR #1

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

Index. Note: Page numbers of article titles are in boldface type.

In - Hospital Diabetes Care. A review and personal experience

6.4 Enteral Nutrition (Other): Gastrostomy vs. Nasogastric feeding January 31 st, 2009

Current Status: Retired PolicyStat ID: Effective: 03/2017 Approved: 03/2017 Last Revised: 03/2017 Expiration: 03/2020

Diabetic Ketoacidosis (DKA) Critical Care Guideline Two Bag System

April Dear (Editor):

This certificate-level program is non-sponsored.

Learning Objectives. Perioperative SWEET Success

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Improved IPGM: Demonstrating the Value to both Patients and Hospitals

Management of Women with Type I Diabetes or Insulin Treated Type II Diabetes

Advances in Diabetes Care Technologies

123 Are You Providing Evidence-Based Diabetes Care? - Martin

My name is Diana Noller from the Medical Team at Sanofi, U.S., and I ll be your host today. I

TOO SWEET TOO STORMY. CONSULTANTS: Dr. Saji James Dr. J. Dhivyalakshmi Dr. P. N. Vinoth. PRESENTOR: Dr. Abhinaya PG I (M.D Paeds)

In-Hospital Management of Diabetes

9.1 Composition of Parenteral Nutrition: Branched Chain Amino Acids (BCAA) March 2013

ESPEN Congress Madrid 2018

Diabetes Care Publish Ahead of Print, published online November 18, 2008

Insulin 10/11/17. Disclosures. Objectives. Speaker and Consultant for Jansen and Healthscripts Speaker and Consultant for Boehringer Ingelheim (BI)

5/22/2012. Organizational Ethics: Keeping It Simple and Real. Frame of Reference. I. The Blueprint of Ethics. SCCE - Alaska Conference June 15, 2012

Diabetes Management: Current High Tech Innovations

Contents available at PubMed Gac Med Mex. 2016;152:680-7

Pump Failure Guidelines

ADMELOG, NOVOLIN, NOVOLOG, and FIASP

Diabetic Ketoacidosis

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Update in Poison Management. Update in Poison Management. Antidote Use. Fomepizole. Pediatric Ingestions 1. No financial disclosures

Guideline on Sick day rules for children and young people with diabetes on insulin

Chapter Goal. Learning Objectives 9/12/2012. Chapter 25. Diabetic Emergencies

New Hires Program Canadian Diabetes Educator Certification Board Competencies Addressed

Local Anesthesia for Dental Hygienists Session III. Altered Consciousness and Diabetes Michael E. O Brien, DDS and Frank S.

CLINICAL UTILITY OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN PATIENTS WITH TYPE 1 DIABETES: A MACEDONIAN REPORT

September 2014 V0.17. Paediatric Daily Fluid Prescription & Balance Chart

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

Getting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite

DKA/HHS Pathway Phase 1 (Adult) Insulin Potassium Bicarbonate

Diagnosis: Allergies:

How to BBIT An Educational Resource for Prescribers AHS Adult Subcutaneous Basal Bolus Insulin Therapy (BBIT)

Text-based Document. Could Music Group Therapy Improve Negative Symptoms of Schizophrenia? Downloaded 28-Jun :19:09

HAP PA-HEN Achieving More Together

Guidance for Insulin Pump (CSII) use in hospital. Information for staff Diabetic Care

Transcription:

Arabian Gulf University Kingdom of Bahrain Year 5 Internal Medicine Critical Appraisal of Medical Article (2) Critical Appraisal (Form A) - What is Your Search question from the case history? How efficient is using insulin in the management of Diabetic Ketoacidosis (DKA) cases? Does it make a difference if you use different types of insulin? - Search questions related to the clinical case: P = Population 20 patients treated with subcutaneous insulin LISPRO were managed in regular medicine wards (n= 10) or an intermediate care unit (n= 10), while 20 patients treated with the intravenous protocol were managed in the Intensive Care Unit (ICU). I = Intervention (treatment or investigation) Patients treated with subcutaneous LISPRO received an initial injection of 0.3 unit/kg followed by 0.1 unit/kg/h until correction of hyperglycemia, followed by 0.05-0.1 unit/kg until resolution of DKA. C = Control those are patients with conventional management who were treated with intravenous regular insulin received as an initial bolus of 0.1 unit/kg followed by an infusion of 0.1 unit/kh/h until correction of hyperglycemia, then 0.05-0.1 unit/kg/h until resolution of DKA. O = Outcome or results The duration of treatment until correction of hyperglycemia and resolution of ketoacidosis in patients treated with subcutaneous LISPRO was not different than in patients treated with intravenous regular insulin. There were no deaths in either groups and there were no differences in the length of hospital stay, amount of insulin until resolution of DKA or in the rate of hypoglycemia between treatment groups.

Critical Appraisal (FORM B) - The title of article Efficacy of Subcutaneous Insulin Lispro versus Continuous Intravenous Regular Insulin for the Treatment of Patients with Diabetic Ketoacidosis. - Name of Journal : American Journal of Medicine - Name of Authors : G.Umpierrez, K.Latif, J.Stoever, R.Cuervo, L.Park, A.Friere and A.Kitabchi. - Year of Publication and Pages : 2004, 6 pages. - What is the Research Question (PICO)? To compare the efficacy and safety of subcutaneous insulin LISPRO with that of a standard low-dose intravenous infusion protocol of regular insulin in patients with uncomplicated DKA. - Is the title of the paper appropriate and does it highlight the major theme of you PICO question? - Is the abstract consistent with the body of the text (Objectives, Designs, Settings, Variables, Data Analysis, results and conclusion)? - Objectives and Hypothesis : Are the objectives of the study clearly stated in the introduction and was it appropriate for the research design? - What is the study design? (tick the proper design) Randomized Controlled trial.

- What is the study population? How they were selected? The sample comprised 40 patients with Diabetic Ketoacidosis (DKA) who were recruited from the Atlanta Medical Center and the Univeristy of Tennessee Health Science Center - Is the data collection open label or blinded for researcher? Open label. - Ethical Considerations - Were ethical considerations mentioned in the article? - Are the results (data presentation in tables) clear? - Discussion and Conclusion? - Did the interpretations of the results and conclusion of the authors fit in with the results presented in the abstract? - Were the objectives of the study clearly accomplished and were they consistent with the discussion? - How do the results apply to your clinical practice? Diabetic Ketoacidosis (DKA) is a medical emergency which you will face frequently in hospital. It is very serious and patients might die if you don t take actions immediately. Therefore, It is of significant importance that you learn how to manage such cases and what specific type of therapy if needed and effective.

Critical Appraisal (Form C) - Relevance of the paper - Does the PICO research question of the study match PICO of your clinical question? - Validity Assessment - Were the patients randomized in the selection? - Was the randomization double or single blinded? Single-blinded - Is the baseline characteristic (age, gender and other risk factors) were similar in the study and the control group of patients? Not mentioned? - Were patients in the groups treated equally aside from the experimental intervention?( in term of follow up and intention to treat analysis ( every patients stay in his group as per randomization) - Was follow-up completed as planned in the method in both groups? - Were the results (outcomes) measured reliably and blindly?

- Applicability Assessment - Is the study population relevant to my practice? (Can the results be applied to my patients?) - Is the intervention relevant (available feasible and affordable) to my practice? - Are all clinical relevant (important) outcomes considered? - Are the likely benefits worth the potential harm and costs?